Skip to main content
Livermore
Livermore
ZHEN

aTYR PHARMA INC

ATYR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001339970

No open-market purchases or sales by aTYR PHARMA INC insiders were filed in the last 90 days; 89 institutions reported holding it in 13F filings for Q2 2026, worth $23.2M in total; no superinvestor holds it.

Holders of 5% or more of ATYR

Holders whose latest Schedule 13D or 13G filing reports 5% or more of aTYR PHARMA INC, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ATYR
HolderLatest formStakeChangeFirst filedLatest filingFiling
Federated Hermes, Inc.13G/A10.76%10.5M shares−6.71 ppfrom 17.47%Jan 8, 20252 filingsOct 7, 2025SEC
BlackRock, Inc.13G6.50%5.76M sharesNewJul 17, 20251 filingJul 17, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

6 Schedule 13D and 13G filings on aTYR PHARMA INC, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ATYR
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 26, 20264:08 PM ETVanguard Group Inc13G/A0.00%0 shares−5.23 ppfrom 5.23%Below 5%Mar 13, 2026SEC
Oct 7, 202511:03 AM ETFederated Hermes, Inc.and 4 others13G/A10.76%10.5M shares−6.71 ppfrom 17.47%Sep 30, 2025SEC
Jul 29, 202511:24 AM ETVanguard Group Inc13G5.23%4.66M sharesNewJun 30, 2025SEC
Jul 17, 20258:12 PM ETBlackRock, Inc.13G6.50%5.76M sharesNewJun 30, 2025SEC
May 15, 20253:55 PM ETPoint72 Asset Management, L.P.and 2 others13G/A3.20%2.85M shares–Below 5%Mar 31, 2025SEC
Jan 8, 20251:38 PM ETFederated Hermes, Inc.and 4 others13G/A17.47%14.7M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell aTYR PHARMA INC shares.

No Form 144 notices for aTYR PHARMA INC are on file.